[Elsevier] Early and late survival dynamics of immunotherapy combinations in advanced HCC: Anchored indirect comparison of atezolizumab plus bevacizumab versus durvalumab +tremelimumab

riazarrej Post time 1 hour(s) ago | Show all posts |Read mode
This post will be closed automatically in 2026-09-08 02:24
Reward10points

journalㄩEuropean Journal of Cancer

AuthorsㄩAndrea Casadei-Gardini; Terry Cheuk-Fung Yip; Alessandro Vitale; Federico Rossari; Toshifumi Tada; Goki Suda; Shigeo Shimose; Masatoshi Kudo; Jaekyung Cheon; Fabian Finkelmeier; Ho Yeong Lim; Jos谷 Presa; Gianluca Masi; Changhoon Yoo; Sara Lonardi; Fabio Piscaglia; Takashi Kumada; Mario Scartozzi; Emiliano Tamburini; Francesco Giuseppe Foschi; Silvia Camera; Mara Persano; Alessandra Pia D*Agata; Michele Ferrara; Laura Passeri; Lorenza Rimassa; Margherita Rimini

Published dateㄩ2026-6-

DOIㄩ10.1016/j.ejca.2026.116750

PDF linkㄩhttps://www.sciencedirect.com/sc ... 959804926005319/pdf

Article linkㄩhttps://doi.org/10.1016/j.ejca.2026.116750

Article SourceㄩElsevier BV


Remarkㄩ
Reply

Use magic Donate Report

All Reply0 Show all posts

Reply

You have to log in before you can reply Login | Register

Points Rules

Junior Member
  • post

  • reply

  • points

    0


Return to the list